Literature DB >> 24273034

Electrical impedance myography correlates with standard measures of ALS severity.

Seward B Rutkove1, James B Caress, Michael S Cartwright, Ted M Burns, Judy Warder, William S David, Namita Goyal, Nicholas J Maragakis, Michael Benatar, Khema R Sharma, Pushpa Narayanaswami, Elizabeth M Raynor, Mary Lou Watson, Jeremy M Shefner.   

Abstract

INTRODUCTION: Electrical impedance myography (EIM) can be used to assess amyotrophic lateral sclerosis (ALS) progression. The relationship between EIM values and standard assessment measures, however, is unknown.
METHODS: EIM 50 kHz phase data from 60 subjects who participated in a longitudinal natural history study of ALS were correlated with handheld dynamometry (HHD), the ALS Functional Rating Scale-Revised (ALSFRS-R) score, and motor unit number estimation (MUNE).
RESULTS: Moderate strength correlations between EIM parameters and HHD were observed for both whole-body and individual upper and lower extremity values. Similarly, moderate strength correlations were observed between EIM and ALSFRS-R upper and lower extremity subscores, but not total ALSFRS-R scores. MUNE correlated significantly with single muscle EIM data but not with whole body or upper or lower extremity values.
CONCLUSIONS: These results support the concept that EIM can serve as a meaningful measure of disease severity in ALS.
Copyright © 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  ALSFRS-R; amyotrophic lateral sclerosis; biomarkers; electrical impedance myography; handheld dynamometry

Mesh:

Year:  2013        PMID: 24273034     DOI: 10.1002/mus.24128

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  34 in total

Review 1.  Toward precision medicine in amyotrophic lateral sclerosis.

Authors:  Zhang-Yu Zou; Chang-Yun Liu; Chun-Hui Che; Hua-Pin Huang
Journal:  Ann Transl Med       Date:  2016-01

Review 2.  Use of biomarkers in ALS drug development and clinical trials.

Authors:  Nadine Bakkar; Ashley Boehringer; Robert Bowser
Journal:  Brain Res       Date:  2014-10-24       Impact factor: 3.252

Review 3.  Clinical Measures of Disease Progression in Amyotrophic Lateral Sclerosis.

Authors:  Seward B Rutkove
Journal:  Neurotherapeutics       Date:  2015-04       Impact factor: 7.620

4.  Electrical impedance myography (EIM) in a natural history study of C9ORF72 mutation carriers.

Authors:  Michelle B Offit; Tianxia Wu; Mary Kay Floeter; Tanya J Lehky
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2020-04-21       Impact factor: 4.092

Review 5.  Hereditary Motor Neuropathies and Amyotrophic Lateral Sclerosis: a Molecular and Clinical Update.

Authors:  Rocio Garcia-Santibanez; Matthew Burford; Robert C Bucelli
Journal:  Curr Neurol Neurosci Rep       Date:  2018-10-17       Impact factor: 5.081

6.  Structural and functional properties of bone are compromised in amyotrophic lateral sclerosis mice.

Authors:  Frank C Ko; Jia Li; Daniel J Brooks; Seward B Rutkove; Mary L Bouxsein
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2018-03-23       Impact factor: 4.092

7.  Assessing the immediate impact of botulinum toxin injection on impedance of spastic muscle.

Authors:  Xiaoyan Li; Henry Shin; Le Li; Elaine Magat; Sheng Li; Ping Zhou
Journal:  Med Eng Phys       Date:  2017-02-04       Impact factor: 2.242

Review 8.  ALS biomarkers for therapy development: State of the field and future directions.

Authors:  Michael Benatar; Kevin Boylan; Andreas Jeromin; Seward B Rutkove; James Berry; Nazem Atassi; Lucie Bruijn
Journal:  Muscle Nerve       Date:  2015-12-29       Impact factor: 3.217

Review 9.  Assessment of Motor Units in Neuromuscular Disease.

Authors:  Robert D Henderson; Pamela A McCombe
Journal:  Neurotherapeutics       Date:  2017-01       Impact factor: 7.620

10.  An improved electrical impedance myography (EIM) tongue array for use in clinical trials.

Authors:  Courtney McIlduff; Sung Yim; Adam Pacheck; Tom Geisbush; Aleksandar Mijailovic; Seward B Rutkove
Journal:  Clin Neurophysiol       Date:  2015-07-02       Impact factor: 3.708

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.